Emerging Markets Earnings Roundup: Bristol Myers Squibb (Part 6)
This article was originally published in PharmAsia News
Bristol Myers Squibb saw some turbulence for Baraclude sales in China and Japan, but noted Yervoy sales lifted and the company has high hopes for a deal with Ono and its Opdivo oncology treatment.
You may also be interested in...
Business development is a top priority for Bristol, management said during the company’s second quarter earnings call, and the focus is on expanding in immuno-oncology portfolio and other core therapeutic areas.
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.